A phase I study of cabozantinib (XL184) in patients with renal cell cancer. - Wikidata - awgldk - TriplyDB

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

http://www.wikidata.org/entity/Q38430335

about

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy Recent advances in the management of renal cell carcinoma c-Met as a Target for Personalized Therapy Met in urological cancers Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.MET Inhibition in Clear Cell Renal Cell Carcinoma Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Kidney cancer and 2014: is innovation really over?Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Targeting the VEGF pathway in metastatic bladder cancer.Emerging drugs for the treatment of bone metastasis.Emerging therapeutic approaches in renal cell carcinoma.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Cabozantinib for the treatment of kidney cancer.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Cabozantinib in genitourinary malignancies.Emerging therapeutics in refractory renal cell carcinoma.Safety of available treatment options for renal cell carcinoma.Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.Cabozantinib for the treatment of renal cell carcinoma.c-Met in chromophobe renal cell carcinoma.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.Targeted therapies for renal cell carcinoma.Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

P2860

Q26741450-E7520856-1937-4780-BD59-15B6AEFC8F48 Q26750609-FE1BD770-CA88-4BFE-8DC7-F6B2AE7EFB76 Q26775483-A4034BC4-80A4-4585-ACD9-4DC67B005F4E Q26864988-A4E11A81-EA10-41B7-8DDA-A3D73BDDE8CE Q28072166-8A082350-6B8E-449F-89EE-C4D621572EFB Q28074834-22BF549C-0006-473B-BD0E-D0587FE8E43D Q34495684-787CD3EB-4E14-436E-A540-4A4CE7D3B108 Q34537725-BD626216-9939-43C6-9CEA-DDEA4B35E0A4 Q34854941-2AF1C66B-922C-4E1F-AF5B-B30990EB9958 Q34978329-57035403-203B-4BD9-A2EB-EE48939EC363 Q35788029-9D27581C-C575-45F3-801B-D6293108F7AB Q35920803-FD2AAF8C-B9CC-4EB6-AFAD-2E9589841122 Q36066539-90580E70-AE98-4674-A9FB-47A5607595F0 Q36095630-5E8614EB-5323-4377-8FE2-4BFDDE69509F Q37067981-A5479EC7-B7EB-47E5-BA93-0D80E7A89325 Q37672483-1AA075E8-F953-4FB1-9D9A-F26B33CB0BA5 Q38465870-1D45B4E1-2A34-41D3-96CC-66AD2EABFD7D Q38485779-AA9B3323-09E0-4F70-A806-8741495C1276 Q38534167-BE92D9AE-C60B-4608-B8D1-29ABE2BEDF15 Q38538263-FE42D1D6-9A0E-4D25-BA45-FA4E3F24AACF Q38587958-ECBEE228-B557-49A5-AAA7-747C9D3A1E5C Q38611436-7473D1C2-D524-4A45-B755-BE7EEBD377A7 Q38668871-400D8096-947A-46A9-8871-FF1F66A7A07A Q38720430-F05274B3-5839-478C-93C5-4A7780CCD9A9 Q38746778-4770EE69-3611-4219-A1D8-C36253C85007 Q38795560-B60B927A-E30C-4874-8328-47F22B7045CA Q38816892-15399A75-4115-48F6-8375-115E648E997D Q38824719-DE6BC005-C5B0-4391-9225-411A951986AB Q38832429-2EFBA2AA-09A4-45B1-B1B5-538AE14EFA0E Q38833200-4ACD02A0-DC11-4570-B0C1-4B36BF0717E0 Q38835745-CEAC436A-4556-4247-A89A-A3A62282533E Q38979283-7B7E3289-FF22-42A8-B98E-AE0E78EBF750 Q39005403-4061B41B-EC3A-4D33-8E15-80A4D74D73E4 Q39051379-DBF2C915-AEE7-4F83-A8D5-9F500D4537FE Q39095194-B02A6B47-711D-47C4-86BF-B46627BDB87C Q39296942-D9B24BA8-5584-487B-B44A-8EF1B0482C33 Q39425380-3736044A-E896-486E-8626-8E6A4C491D06 Q41099660-C23A57B1-B8AE-4866-94B8-7515C2606C43 Q42203109-8D76698D-AC56-4E0C-A178-14B028E058D3 Q42257155-3728910F-FB8C-4C39-9EC2-88B22CCBE0B7

P2860

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

http://www.wikidata.org/entity/Q38430335

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

@en

type

label

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

@en

prefLabel

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

@en

P1433

Q38430335-FB0AD7A1-3001-4B30-A5D0-8082FA12C4A8

P1476

Q38430335-BDB85CF4-1B4B-4CE4-B372-D6F0EA798A34

P2093

Q38430335-14FAF1E1-6B64-40C4-9E16-D4C578D78F9A

Q38430335-3961FDD5-3AAD-4A56-B648-72F6A3E3FB3A

Q38430335-6101A1D2-2347-49EC-BA27-E4794CF74D5E

Q38430335-82806C8C-E4CE-4ED3-B21E-2492370C4EC1

Q38430335-8DE6DA64-98EE-4DF9-A90A-19DBEEE6D38E

Q38430335-973178E8-EF04-4A40-ACA0-CD40BFCFDF42

Q38430335-F67FEDC4-DA9A-4656-89D6-CA23D1D0129B

Q38430335-FB1B7235-4CFD-4759-B6D2-4EC2DE3BBEE2

P2860

Q38430335-07638DA8-A393-4F07-8A16-E589FDA50CAB

Q38430335-0D734EB8-35C1-4312-80CF-47E6DA9DA69C

Q38430335-228BBA2A-42EE-4666-B3B0-3335DD154583

Q38430335-36340306-9FC9-48B2-889D-D9DD291A6586

Q38430335-3CA932F3-08CB-4473-B79D-775D6117DB70

Q38430335-46CB31D4-1155-40C3-89AC-091763737669

Q38430335-46DEFEF6-F9A3-4CE0-A0CD-7A521E1D893A

Q38430335-4FE6FC71-1B76-4B34-BAA1-77F5E026C336

Q38430335-50239E1F-E69D-4E64-AC5C-7CDDD98EB0AE

Q38430335-58993667-45A6-423A-B3AE-B4D7368B2C2A

P304

Q38430335-C08F0C48-4F40-4240-8524-D3FCE0C29972

P31

Q38430335-45B53FE4-7E9C-485A-8D1C-8BF9FEF9170C

P356

Q38430335-23C3205C-561A-47ED-B2AB-02F85B4CD305

P433

Q38430335-624A4876-20CB-4B96-9F0B-A8AF523B1091

P478

Q38430335-3691D3EC-164C-4860-847F-B584DE3C9F5D

P577

Q38430335-D76D0AC0-CFDE-42C8-9362-1C877494C635

P5875

Q38430335-257287E6-0FC4-4FE5-B3F1-51309C997165

P698

Q38430335-069B4070-0349-455C-9ABA-829C0EBBE086

P932

Q38430335-694C628D-3C09-4226-AA5C-604227735AD5

P356

P1433

Annals of Oncology

P1476

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

@en

P2093

D F McDermott

http://www.w3.org/2001/XMLSchema#string

J Holland

http://www.w3.org/2001/XMLSchema#string

J P Dutcher

http://www.w3.org/2001/XMLSchema#string

K C Ferguson

http://www.w3.org/2001/XMLSchema#string

S K Pal

http://www.w3.org/2001/XMLSchema#string

S Morrissey

http://www.w3.org/2001/XMLSchema#string

T K Choueiri

http://www.w3.org/2001/XMLSchema#string

W G Kaelin

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Cabozantinib in progressive medullary thyroid cancer.

Clinical features of metastatic bone disease and risk of skeletal morbidity.

P304

1603-1608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU184

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262338889

http://www.w3.org/2001/XMLSchema#string

P698

24827131

http://www.w3.org/2001/XMLSchema#string

P932

6279111

http://www.w3.org/2001/XMLSchema#string